Updated:
Sail Biomedicines
Sail Biomedicines was launched in October 2023 by Flagship Pioneering, consolidating eight years of combined data and platform assets from across its...
Sail Biomedicines
Sail Biomedicines was launched in October 2023 by Flagship Pioneering, consolidating eight years of combined data and platform assets from across its ecosystem. John Mendlein, a former Moderna executive who joined Flagship in 2019, serves as Executive Chairman. The firm's technology originates from Flagship Labs and other portfolio companies, focusing on programmable RNA medicines. The company's platform combines Endless RNA (eRNA), a circular RNA that enables durable protein expression, with targeted nanoparticles (TNPs) that deliver payloads to specific cells. Sail also deploys proprietary generative AI to design these medicines. The firm targets autoimmune, metabolic, infectious, and rare diseases, with an initial vanguard program for in vivo eRNA-TNP CAR-T for autoimmune indications. It operates across the United States, with a research focus that leverages collaborators such as Moderna and other Flagship entities. Sail has a leadership team of approximately 10 professionals, including former Merck, Biogen, and Pfizer executives. The firm is headquartered in the United States and does not disclose its number of employees or total funding. No recent operational event in the past 24 months was publicly reported beyond its formation. Sail's structural differentiator is its origin within the Flagship Pioneering venture creation model, which provides access to a broad ecosystem of platform technologies and scientific talent. Unlike a standalone biotech, Sail was assembled from pre-existing Flagship assets, giving it a head start in data and platform maturity.
General information
Firm type
Asset Manager
Year founded
2023
AUM
Undisclosed
Location
Region
North America
Country
United States
City
United States
Corporate office
United States
Principals
John Mendlein
Executive Chairman
Gene Marcantonio
Chief Medical Officer
Ewen Cameron
SVP, Platform
Amy Espeseth
Head of Pharmacology and Vaccines
Vincent Hennemand
Chief Product & Operations Officer
Rafal Kowalczyk
Head of Finance
Michael Mingueneau
SVP, Head of Immunology
Jim Nolan
SVP, Head of Technical Development & Operations
Mark Umbarger
Head of Artificial Intelligence & Digital Sciences
Michael Lam
Vice President, Strategy & Scientific External Affairs
Sector focus
Frequently asked questions
Who leads investment decisions at Sail Biomedicines?
John Mendlein serves as Executive Chairman and is the most senior executive, with a background at Moderna and Flagship Pioneering. The board includes Flagship partners and independent directors such as Pablo Cagnoni (Incyte) and Frank D'Amelio (former Pfizer CFO). Investment decisions around platform development and pipeline prioritization are made by the leadership team and board, per the firm's website.
How does Sail Biomedicines source its technology?
Sail was formed by Flagship Pioneering, consolidating technologies developed across its ecosystem, including eRNA from Laronde (a Flagship company) and targeted nanoparticle work from other portfolio firms. The platform integrates these assets with proprietary AI for medicine design.
Is Sail Biomedicines structured as a single family office or a venture-backed biotech?
Sail is a private biotechnology company, not a family office. It is majority-owned by Flagship Pioneering, a venture creation firm, and operates with a standard corporate structure: executive team, board, and advisory members.
Does Sail Biomedicines participate in fund commitments or only direct R&D?
Sail is an operating company focused on internal drug discovery and development. It does not manage external capital or make fund commitments. Its financial support comes from Flagship and potentially other investors, though fundraising details are not disclosed.
What investment stages does Sail Biomedicines target?
Sail is a preclinical-stage biotech platform company. It is building a pipeline of candidate medicines for autoimmune, metabolic, infectious, and rare diseases, with an initial focus on advancing an in vivo CAR-T program toward clinical trials.
Which therapeutic areas does Sail Biomedicines explicitly avoid?
Sail does not publicly disclose any excluded therapeutic areas. Its stated pipeline targets autoimmune, metabolic, infectious, and rare diseases, suggesting a broad focus within RNA medicine.
How is Sail Biomedicines related to Flagship Pioneering?
Sail is a Flagship Pioneering company, meaning it was conceived and built within Flagship's venture creation engine. Flagship provides strategic, operational, and financial support, and several Flagship executives and partners sit on Sail's board.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: